24.800
-0.700
(-2.75%)
At close: January 28 at 12:08:04 PM GMT+8
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
2,726,451.261
2,634,910.000
2,103,438.000
1,750,116.000
1,324,427.000
Cost of Revenue
815,283.987
781,401.000
656,515.000
490,370.000
334,004.000
Gross Profit
1,911,167.274
1,853,509.000
1,446,923.000
1,259,746.000
990,423.000
Operating Expense
1,649,879.069
1,415,132.000
1,226,752.000
1,032,151.000
865,078.000
Operating Income
261,288.205
438,377.000
220,171.000
227,595.000
125,345.000
Net Non Operating Interest Income Expense
77,105.753
70,436.000
80,280.000
93,247.000
103,554.000
Pretax Income
520,954.764
508,260.000
235,726.000
382,649.000
257,026.000
Tax Provision
99,714.584
95,991.000
45,395.000
35,366.000
30,686.000
Net Income Common Stockholders
446,169.943
416,121.000
180,470.000
352,234.000
230,072.000
Diluted NI Available to Com Stockholders
446,169.943
416,121.000
180,470.000
352,234.000
230,072.000
Basic EPS
1.89
1.74
0.74
1.43
0.93
Diluted EPS
1.89
1.74
0.74
1.43
0.93
Basic Average Shares
235,898.137
238,743.591
242,987.885
246,575.291
248,124.811
Diluted Average Shares
235,898.137
238,743.591
242,987.885
246,575.291
248,124.811
Rent Expense Supplemental
--
4,652.000
4,562.000
--
--
Total Expenses
2,465,163.056
2,196,533.000
1,883,267.000
1,522,521.000
1,199,082.000
Net Income from Continuing & Discontinued Operation
446,169.943
416,121.000
180,470.000
352,234.000
230,072.000
Normalized Income
447,550.932
414,009.800
192,842.117
349,344.744
228,865.911
Interest Income
75,380.025
77,731.000
87,883.000
98,210.000
108,459.000
Interest Expense
11,146.226
7,295.000
7,603.000
4,963.000
4,905.000
Net Interest Income
77,105.753
70,436.000
80,280.000
93,247.000
103,554.000
EBIT
532,100.990
515,555.000
243,329.000
387,612.000
261,931.000
EBITDA
532,100.990
713,410.000
447,546.000
550,449.000
394,802.000
Reconciled Cost of Revenue
815,283.987
781,401.000
656,515.000
490,370.000
334,004.000
Reconciled Depreciation
--
197,855.000
204,217.000
162,837.000
132,871.000
Net Income from Continuing Operation Net Minority Interest
446,169.943
416,121.000
180,470.000
352,234.000
230,072.000
Total Unusual Items Excluding Goodwill
-1,707.891
2,600.000
-15,331.000
3,182.000
1,369.000
Total Unusual Items
-1,707.891
2,600.000
-15,331.000
3,182.000
1,369.000
Normalized EBITDA
533,808.882
710,810.000
462,877.000
547,267.000
393,433.000
Tax Rate for Calcs
0.000
0.000
0.000
0.000
0.000
Tax Effect of Unusual Items
-326.903
488.800
-2,958.883
292.744
162.911
12/31/2020 - 4/30/2015
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
2171.HK CARsgen Therapeutics Holdings Limited
10.080
-2.51%
6821.HK Asymchem Laboratories (Tianjin) Co., Ltd.
49.500
-1.00%
6660.HK AIM Vaccine Co., Ltd.
5.800
-1.19%
2157.HK Lepu Biopharma Co., Ltd.
2.730
-4.88%
2197.HK Clover Biopharmaceuticals, Ltd.
0.218
-0.91%
2257.HK Sirnaomics Ltd.
2.890
+4.33%
3759.HK Pharmaron Beijing Co., Ltd.
14.100
-1.40%
6990.HK Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
159.300
-0.62%
1952.HK Everest Medicines Limited
40.300
-0.86%
9688.HK Zai Lab Limited
20.900
+1.95%